Abstract:Cancer cells often encounter hypoxic and hypo-nutrient conditions, which force them to make adaptive changes to meet their high demands for energy and various biomaterials for biomass synthesis. As a result, enhanced catabolism (breakdown of macromolecules for energy production) and anabolism (macromolecule synthesis from bio-precursors) are induced in cancer. This phenomenon is called "metabolic reprogramming," a cancer hallmark contributing to cancer development, metastasis, and drug resistance. HCC and cholangiocarcinoma (CCA) are 2 different liver cancers with high intertumoral heterogeneity in terms of etiologies, mutational landscapes, transcriptomes, and histological representations. In agreement, metabolism in HCC or CCA is remarkably heterogeneous, although changes in the glycolytic pathways and an increase in the generation of lactate (the Warburg effect) have been frequently detected in those tumors. For example, HCC tumors with activated β-catenin are addicted to fatty acid catabolism, whereas HCC tumors derived from fatty liver avoid using fatty acids. In this review, we describe common metabolic alterations in HCC and CCA as well as metabolic features unique for their subsets. We discuss metabolism of NAFLD as well, because NAFLD will likely become a leading etiology of liver cancer in the coming years due to the obesity epidemic in the Western world. Furthermore, we outline the clinical implication of liver cancer metabolism and highlight the computation and systems biology approaches, such as genome-wide metabolic models, as a valuable tool allowing us to identify therapeutic targets and develop personalized treatments for liver cancer patients.

Metabolic Heterogeneity in Cancer: an Overview and Therapeutic Implications

Metabolic heterogeneity in cancer

Metabolic regulation of tumor-associated macrophage heterogeneity: insights into the tumor microenvironment and immunotherapeutic opportunities

The Many Facets of Tumor Heterogeneity: Is Metabolism Lagging Behind?

Cancer metabolism and carcinogenesis

Cancer Metabolism and Intervention Therapy

Metabolic rearrangements and intratumoral heterogeneity for immune response in hepatocellular carcinoma

Metabolic reprogramming of carcinoma-associated fibroblasts and its impact on metabolic heterogeneity of tumors

Heterogeneity in Primary Tumors and Corresponding Metastases: Could It Provide Us with Any Hints to Personalize Cancer Therapy?

Bulk and single-cell transcriptome profiling reveal the metabolic heterogeneity in human breast cancers

The metabolic crosstalk of cancer-associated fibroblasts and tumor cells: Recent advances and future perspectives

Effects of Glucose Metabolism, Lipid Metabolism, and Glutamine Metabolism on Tumor Microenvironment and Clinical Implications

Metabolic reprogramming and its clinical implication for liver cancer

Metabolomics at the tumor microenvironment interface: Decoding cellular conversations

Metabolic Regulation of Prostate Cancer Heterogeneity and Plasticity.

Metabolic Landscape of the Tumor Microenvironment at Single Cell Resolution

Heterogeneity of the tumor immune microenvironment and its clinical relevance

Metabolic Heterogeneity and Potential Immunotherapeutic Responses Revealed by Single-Cell Transcriptomics of Breast Cancer

Metabolic heterogeneity signature of primary treatment-naïve prostate cancer

Altered metabolism in cancer: insights into energy pathways and therapeutic targets